

# 1 Deep learning enables therapeutic antibody optimization in 2 mammalian cells by deciphering high-dimensional protein 3 sequence space

4 Derek M Mason<sup>1</sup>, Simon Friedensohn<sup>1</sup>, Cédric R Weber<sup>1</sup>, Christian Jordi<sup>1</sup>, Bastian Wagner<sup>1</sup>, Simon  
5 Meng<sup>1</sup>, Pablo Gainza<sup>2</sup>, Bruno E Correia<sup>2</sup> and Sai T Reddy<sup>1\*</sup>

6  
7 <sup>1</sup>Department of Biosystems Science and Engineering, ETH Zurich, 4058, Basel, Switzerland

8 <sup>2</sup>Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, 1015, Lausanne, Switzerland

9  
10 Correspondence: \*[sai.reddy@ethz.ch](mailto:sai.reddy@ethz.ch)

## 12 ABSTRACT (150 words)

13 Therapeutic antibody optimization is time and resource intensive, largely because it requires  
14 low-throughput screening ( $10^3$  variants) of full-length IgG in mammalian cells, typically resulting  
15 in only a few optimized leads. Here, we use deep learning to interrogate and predict antigen-  
16 specificity from a massively diverse sequence space to identify globally optimized antibody  
17 variants. Using a mammalian display platform and the therapeutic antibody trastuzumab,  
18 rationally designed site-directed mutagenesis libraries are introduced by CRISPR/Cas9-  
19 mediated homology-directed repair (HDR). Screening and deep sequencing of relatively small  
20 libraries ( $10^4$ ) produced high quality data capable of training deep neural networks that  
21 accurately predict antigen-binding based on antibody sequence. Deep learning is then used to  
22 predict millions of antigen binders from an *in silico* library of  $\sim 10^8$  variants, where experimental  
23 testing of 30 randomly selected variants showed all 30 retained antigen specificity. The full set  
24 of *in silico* predicted binders is then subjected to multiple developability filters, resulting in  
25 thousands of highly-optimized lead candidates. With its scalability and capacity to interrogate  
26 high-dimensional protein sequence space, deep learning offers great potential for antibody  
27 engineering and optimization.

28  
29

## 30 INTRODUCTION

31 In antibody drug discovery, the ‘target-to-hit’ stage is a well-established process, as screening  
32 hybridomas, phage or yeast display libraries typically result in a number of potential lead candidates.  
33 However, the time and costs associated with lead candidate optimization often take up the majority of  
34 the preclinical discovery and development cycle<sup>1</sup>. This is largely due to the fact that lead optimization  
35 of antibody molecules consists of addressing multiple parameters in parallel, including expression level,  
36 viscosity, pharmacokinetics, solubility, and immunogenicity<sup>2,3</sup>. Once a lead candidate is discovered,  
37 additional engineering is often required; phage and yeast display offer a powerful method for high-  
38 throughput screening of large mutagenesis libraries ( $>10^9$ ), however they are primarily only used for  
39 increasing affinity or specificity to the target antigen<sup>4</sup>. The fact that nearly all therapeutic antibodies  
40 require expression in mammalian cells as full-length IgG means that the remaining development and  
41 optimization steps must occur in this context. Since mammalian cells lack the capability to stably

*Deep learning enables therapeutic antibody optimization in mammalian cells*

42 replicate plasmids, this last stage of development is done at very low-throughput, as elaborate cloning,  
43 transfection and purification strategies must be implemented to screen libraries in the max range of  $10^3$ ,  
44 meaning only minor changes (e.g., point mutations) are screened<sup>5</sup>. Interrogating such a small fraction  
45 of protein sequence space also implies that addressing one development issue will frequently cause  
46 rise of another or even diminish antigen binding altogether, making multi-parameter optimization very  
47 challenging. This challenge frequently results in antibodies with suboptimal biophysical properties for  
48 clinical development, which can lead to adverse side effects or even drug failure. For example, self-  
49 administered, subcutaneous injection of antibodies is becoming an increasingly used approach for  
50 patients requiring frequent dosing, but the identification of highly soluble, non-viscous antibodies which  
51 retain high biological activity is immensely difficult<sup>6</sup>. The withdrawal of Pfizer's anti-PCSK9 antibody,  
52 bococizumab, from clinical trials is an even more drastic example, where the immunogenicity of the  
53 molecule adversely effected long-term treatment efficacy. Conversely, Sanofi and Regeneron's  
54 clinically approved antibody, alirocumab, has the same molecular target of PCSK9, but shows almost  
55 no immunogenic effects<sup>7</sup>.

56 Machine learning applied to biological sequence data offers a powerful approach to augment protein  
57 engineering by constructing models capable of making predictions of genotype-phenotype  
58 relationships<sup>8,9</sup>. This is due to the capability of models to extrapolate complex relationships between  
59 sequence and function. One of the principle challenges in constructing accurate machine learning  
60 models is the collection of appropriate high-quality training data. Directed evolution platforms are well-  
61 suited for this as they rely on the linking of biological sequence data (DNA, RNA, protein) to a phenotypic  
62 output<sup>10</sup>. In fact, it has long been proposed to use machine learning models trained on data generated  
63 by mutagenesis libraries as a means to guide protein engineering<sup>11,12</sup>. Recently, Gaussian processes,  
64 a Bayesian learning model, were used to engineer cytochrome enzymes, enabling navigation through  
65 a vast protein sequence space to discover highly thermostable variants<sup>13</sup>. Similarly, the design and  
66 screening of a structure-guided library of channel rhodopsin membrane proteins was used to train  
67 Gaussian process regression models, which were able to accurately predict variants that could express  
68 and localize on mammalian cell membranes<sup>14</sup>.

69 In recent years, access to deep sequencing and parallel computing has enabled the construction of  
70 deep learning models capable of predicting molecular phenotype from sequence data<sup>15,16</sup>. For example,  
71 deep learning has been used to learn the sequence specificities of RNA- and DNA-binding proteins<sup>17</sup>,  
72 regulatory grammar of protein expression in yeast<sup>18</sup>, and HLA-neoantigen presentation on tumor cells<sup>19</sup>.  
73 In most cases deep (artificial) neural networks represent the class of algorithm utilized. While the  
74 complexity of neural networks has changed drastically since their conception, the fundamental concept  
75 remains the same: mimicking the connections of biological neurons to learn complex relationships  
76 between variables<sup>20</sup>. As an extension of a single-layer neural network, or perceptron<sup>21</sup>, deep learning  
77 incorporates multiple hidden layers to decipher relationships buried in large, high-dimensional data sets,  
78 such as the millions of reads gathered from a single deep sequencing experiment. Well trained models  
79 can then be used to make predictions on completely unseen and novel variants. This application of  
80 model extrapolation lends itself perfectly to protein engineering because it provides a way to interrogate  
81 a much larger sequence space than what is physically possible. For example, even for a short stretch

Deep learning enables therapeutic antibody optimization in mammalian cells

82 of just 10 amino acids, the combinatorial sequence diversity explodes to  $10^{13}$ , a size which is nearly  
83 impossible to interrogate experimentally.

84 Here, we leverage the power of deep learning to perform multi-parameter optimization of therapeutic  
85 antibodies (full-length IgG) directly in mammalian cells (Figure 1). Starting with a mammalian display  
86 cell line<sup>22</sup> expressing the therapeutic antibody trastuzumab (Herceptin), we use CRISPR-Cas9-  
87 mediated homology-directed repair (HDR) to introduce site-directed mutagenesis libraries in the  
88 variable heavy chain complementarity determining region 3 (CDRH3)<sup>23</sup>. In order to generate information  
89 rich training data, single-site deep mutational scanning (DMS) is first performed<sup>24</sup>, which is then used  
90 to guide the design of combinatorial mutagenesis libraries. An experimental (physical) library size of  $5 \times 10^4$  variants  
91 was then screened for specificity to the antigen HER2. All binding and non-binding variant  
92 sequences were then used to train recurrent and convolutional deep neural networks, which when fully-  
93 trained and optimized were able with high accuracy and precision to predict antigen-specificity based  
94 on antibody sequence. Neural networks are then used to predict antigen-specificity on a subset of  
95 sequence variants from the DMS-based combinatorial mutagenesis library ( $\sim 10^8$  sequences), resulting  
96 in  $> 3.0 \times 10^6$  variants predicted to have a high probability of being antigen-specific. A random selection  
97 of variants were recombinantly expressed and tested, resulting in 30 out of 30 showing antigen-specific  
98 binding. The *in silico* library of predicted binders are then subjected to several sequence-based *in silico*  
99 filtering steps to optimize for developability parameters such as viscosity, clearance, solubility and  
100 immunogenicity, resulting in nearly 5,000 antibody sequence variants predicted to have more optimal  
101 properties than the starting trastuzumab sequence.

102 **RESULTS**

103 **Deep mutational scanning determines antigen-specific sequence landscapes and guides  
104 rational antibody library design**

105 As the amino acid sequence of an antibody's CDRH3 is a key determinant of antigen specificity, we  
106 performed DMS on this region to resolve the specificity determining residues. To start, a hybridoma  
107 cell-line was used that expressed a trastuzumab variant that could not bind HER2 antigen (mutated  
108 CDRH3 sequence) (Supplementary Fig. 1). Libraries were generated by CRISPR-Cas9-mediated  
109 homology-directed mutagenesis (HDM)<sup>23</sup> by transfecting guide RNA (gRNA) targeting the CDRH3 and  
110 a pool of homology templates in the form of single-stranded oligonucleotides (ssODNs) containing NNK  
111 degenerate codons at single-sites tiled across CDRH3 (Figure 2a, Supplementary Fig. 2). Libraries  
112 were then screened by fluorescence activated cell sorting (FACS), and populations expressing surface  
113 IgG which either were binding or not binding to antigen were isolated and subjected to deep sequencing  
114 (Illumina MiSeq) (Supplementary Table 1). Deep sequencing data was then used to calculate  
115 enrichment scores of the 10 positions investigated, which revealed six positions that were sufficiently  
116 amenable to a wide-range of mutations and an additional three positions that were marginally accepting  
117 to defined mutations (Figure 2b). Although residues 102D, 103G, 104F, and 105Y appear to be  
118 contacting amino acids of the CDRH3 loop with HER2<sup>25,26</sup>, 105Y is the only residue completely fixed.  
119 In addition to DMS, we also explored the capacity of structural modeling to identify the prospective  
120 antigen-binding landscape by using structure-guided modeling with Rosetta, a leading software platform

*Deep learning enables therapeutic antibody optimization in mammalian cells*

121 for computational protein design<sup>27</sup>. After performing 5,000 redesigns of trastuzumab (PDB id: 1N8Z),  
122 preceded by a stochastic backbone flexibility (FastRelax) step, 48 possible variants were generated  
123 (Figure 2c). The resulting sequence logo plot from these generated variants, however, differed  
124 substantially from the DMS-based sequence logo plot.

125 The limited number of predictions and diversity from Rosetta suggested that sequence logo plots  
126 generated by DMS are a better option to guide the rational design of a combinatorial mutagenesis  
127 library, which consisted of degenerate codons across all positions (except 105Y) (Supplementary Fig.  
128 3, Supplementary Table 7). Degenerate codons were selected per position based on their amino acid  
129 frequencies which most closely resembled the degree of enrichment found in the DMS data following  
130 1, 2, and 3 rounds of antigen-specific enrichment (Supplementary Fig. 2, Equation 2). This  
131 combinatorial library possesses a theoretical protein sequence space of  $7.17 \times 10^8$ , far greater than the  
132 single-site DMS library diversity of 200. Libraries containing CDRH3 variants were again generated in  
133 hybridoma cells through CRISPR-Cas9-mediated HDM in the same non-binding trastuzumab clone  
134 described previously (Figure 2d). Antigen binding cells were isolated by two rounds of enrichment by  
135 FACS (Figure 2d, Supplementary Fig. 3) and the binding/non-binding populations were subjected to  
136 deep sequencing. Sequencing data identified 11,300 and 27,539 unique binders and non-binders,  
137 respectively (Supplementary Table 2). These sequence variants represented only a minuscule 0.0054%  
138 of the theoretical protein sequence space of the combinatorial mutagenesis library.

139 Discriminating between the binding and non-binding sequences in the combinatorial library is  
140 challenging at the sequence level. Amino acid usage per position was comparatively similar between  
141 antigen binding and non-binding populations (Figure 2e), thus making it difficult to develop any sort of  
142 heuristic rules or decipher observable patterns to identify binding sequences. Thus, we investigated  
143 whether structure-based analysis could accurately predict antigen-binding sequences. We used  
144 Rosetta to model each of the 11,300 binder and 27,539 non-binder sequences from the combinatorial  
145 library on the antibody structure of trastuzumab, and used Rosetta's predicted free energy of binding  
146 (ddG) as the discrimination score. This approach, however, yielded a very poor classifier (ROC curve  
147 AUC: 0.55, Figure 2f) and revealed that high-dimensional patterns determining antigen-specificity could  
148 not be extracted by structural modeling.

**149 Training deep neural networks to classify antigen-specificity based on antibody sequence**

150 To learn the high-dimensional patterns that determine antigen binding, we set out to develop and train  
151 sequence-based deep learning models capable of predicting antibody specificity towards the target  
152 antigen HER2. After having compiled deep sequencing data on binding and non-binding CDRH3  
153 variants, amino acid sequences were converted to an input matrix by one-hot encoding, an approach  
154 where each column of the matrix represents a specific residue and each row corresponds to the position  
155 in the sequence, thus a 10 amino acid CDRH3 sequence as here results in a 10 x 20 matrix. Each row  
156 will contain a single '1' in the column corresponding to the residue at that position, whereby all other  
157 columns/rows receive a '0'. We utilized long short-term memory recurrent neural networks (LSTM-RNN)  
158 and convolutional neural networks (CNN), which represent two of the main classes of deep learning

*Deep learning enables therapeutic antibody optimization in mammalian cells*

159 models used for biological sequence data<sup>16</sup>. LSTM-RNNs and CNNs both stem from standard neural  
160 networks, where information is passed along neurons that contain learnable weights and biases,  
161 however, there are fundamental differences in how the information is processed. LSTM-RNN layers  
162 contain loops, enabling information to be retained from one step to the next, allowing models to  
163 efficiently correlate a sequential order with a given output; CNNs, on the other hand, apply learnable  
164 filters to the input data, allowing it to efficiently recognize spatial dependencies associated with a given  
165 output. Model architecture and hyperparameters (Figures 3a, c) were selected by performing a grid  
166 search across various parameters (LSTM-RNN: nodes per layer, batch size, number epochs and  
167 optimizing function; CNN: number of filters, kernel size, dropout rate and dense layer nodes) using a k-  
168 fold cross-validation of the data set. All models were built to assess their accuracy and precision of  
169 classifying binders and non-binders from the available sequencing data. 70% of the original data set  
170 was used to train the models and the remaining 30% was split into two test data sets used for model  
171 evaluation: one test data set contained the same class split of sequences used to train the model and  
172 the other contained a class split of approximately 10/90 binders/non-binders to resemble physiological  
173 frequencies (Figure 2d). Performance of the LSTM-RNN and CNN were assessed by constructing  
174 receiver operating characteristic (ROC) curves and precision-recall (PR) curves derived from  
175 predictions on the unseen testing data sets (Figure 3b, d). Based on conventional approaches to training  
176 classification models, the data set was adjusted to allow for a 50/50 split of binders and non-binders  
177 during training. Under these training conditions, the LSTM-RNN and CNN were both able to accurately  
178 classify unseen test data (ROC curve AUC:  $0.9 \pm 0.0$ , average precision:  $0.9 \pm 0.0$ , Supplementary Fig.  
179 5).

180 Next, we used the trained LSTM-RNN and CNN models to classify a random sample of  $1 \times 10^5$   
181 sequences from the potential sequence space. We observed, however, an unexpectedly high  
182 occurrence of positive classifications ( $25,318 \pm 1,643$  sequences or  $25.3 \pm 1.6\%$ , Supplementary Table  
183 3b). With the knowledge that the physiological frequency of binders should be approximately 10-15%,  
184 we sought to adjust the classification split of the training data with the hypothesis that models were  
185 being subject to some unknown classification bias. Additional models were then trained on classification  
186 splits of both 20/80, and 10/90 binders/non-binders, as well as a classification split with all available  
187 data (approximately 30/70 binders/non-binders). Unbalancing the sequence classification led to a  
188 significant reduction in the percentage of sequences classified as binders, but also led to a reduction in  
189 the model performance on the unseen test data (Supplementary Fig. 4-7, Supplementary Tables 3a,  
190 b). Through our analysis, we concluded that the optimal data set for training the models was the set  
191 inclusive of all known CDRH3 sequences for the following reasons: 1) the percentage of sequences  
192 predicted as binders reflects this physiological frequency, 2) this data set maximizes the information  
193 the model sees, and 3) model performance on both test data sets. Final model architecture, parameters,  
194 and evaluation are shown in Figure 3. As a final measure of model validation, neural networks were  
195 trained with a data set containing randomly shuffled binding and non-binding class labels. Model  
196 performance of these networks revealed indiscriminate sequence classification on unseen test data  
197 (Supplementary Fig. 8), signifying the identification of learned patterns for networks trained with  
198 properly classified data.

Deep learning enables therapeutic antibody optimization in mammalian cells

199 **Predicted binding sequences are recombinantly expressed and antigen-specific**

200 Using our DMS-based combinatorial mutagenesis library as a guide (Figure 2d),  $7.2 \times 10^7$  possible  
201 sequence variants were generated in silico. The fully-trained LSTM-RNN and CNN models were used  
202 to classify all  $7.2 \times 10^7$  sequence variants as either antigen binders or non-binders based on a probability  
203 score ( $P$ ), resulting in a prediction of  $8.55 \times 10^6$  (LSTM-RNN) and  $9.52 \times 10^6$  (CNN) potential binders  
204 ( $P > 0.50$ ). This represented a reasonable fraction (11-13%) of antigen-specific variants based on  
205 experimental screening (Figure 2d). To increase confidence, we increased the prediction threshold for  
206 binder classification to  $P > 0.75$  and took the consensus binders between the LSTM-RNN and CNN.  
207 This reduced the antigen-specific sequence space down to  $3.1 \times 10^6$  variants. To validate the precision  
208 of our fully trained LSTM-RNN and CNN models, we randomly selected and tested a subset of 30  
209 CDRH3 sequences predicted to be antigen-specific (Figure 4a). To further demonstrate the capacity of  
210 deep learning to identify novel sequence variants, we also added the criteria that the selected variants  
211 must have a minimum Levenshtein distance ( $LD$ ) of 5 from the original CDRH3 sequence of  
212 trastuzumab. CRISPR-Cas9-mediated HDR was used to generate mammalian display cell lines  
213 expressing the 30 different sequence variants. Flow cytometry was performed and revealed that 30 of  
214 the 30 variants (100%) were antigen-specific (Supplementary Fig. 9). Further analysis was performed  
215 on the 30 antigen-binding variants to more precisely quantify the binding kinetics via biolayer  
216 interferometry (BLI, FortéBio Octet RED96e) (Figure 4b). The original trastuzumab sequence was  
217 measured to have an affinity towards HER2 of  $4.0 \times 10^{-10}$  M (equilibrium dissociation constant,  $K_D$ ); and  
218 although the majority of variants tested had a slight decrease in affinity, 80% (24/30) were still in the  
219 single-digit nanomolar range, 17% (5/30) remained sub-nanomolar, and even one variant (3%) showed  
220 a near 3-fold increase in affinity compared to trastuzumab ( $K_D = 1.4 \times 10^{-10}$  M) (Figure 4a, c). We also  
221 investigated if there were correlations between model prediction values and measured affinities  
222 (Supplementary Fig. 10). While no strong trend was observable, the highest affinity variants tended to  
223 have higher prediction values.

224 **Sequence space analysis of deep learning predicted variants**

225 In order to investigate the sequence space of the predicted binding and non-binding variants, we  
226 conducted a sequence similarity network analysis<sup>28</sup> of 5,000 randomly selected binding and non-binding  
227 sequences (Supplementary Table 4, Supplementary Fig. 11). When generating similarity networks by  
228 clustering CDRH3 sequences with a  $LD \leq 3$ , we observed 99.7% of all sequences to be within a single  
229 cluster, but when increasing the clustering stringency to a  $LD \leq 2$ , the fraction of sequences found within  
230 the largest cluster is reduced to 30%, with the majority of other sequences not clustering with any other  
231 sequence (Figure 5a). While a large portion of the sequences found within the largest cluster are  
232 predicted binding sequences, non-binding sequences are also present, illustrating the complexities of  
233 the patterns identified by deep neural networks. To further elucidate the high-dimensional patterns of  
234 the antigen-binding landscape that deep learning models have identified, we performed the attribution  
235 method of *Integrated Gradients*<sup>29</sup> on closely related sequences ( $LD \leq 2$ ) (Figure 5b). This analysis  
236 provides a means to visualize non-linear combinations of amino acids that contribute to classification  
237 as a binder or non-binder. This revealed that unlike position-weight matrices, LSTM-RNN and CNN

Deep learning enables therapeutic antibody optimization in mammalian cells

238 models did not equally weight individual residues and positions and thus learned complex non-linear  
239 patterns associated with binding and non-binding.

240 **Multi-parameter optimization for developability by in silico screening of antibody sequence  
241 space**

242 Next, we characterized the full  $3.1 \times 10^6$  deep learning predicted antigen-specific sequences on a  
243 number of parameters to identify highly developable candidates compared to the original trastuzumab  
244 sequence. As a preliminary metric, we investigated their sequence similarity to the original trastuzumab  
245 sequence by calculating the *LD*. The majority of sequences showed an edit distance of  $LD > 4$  (Figure  
246 6a). The first step in filtering was to calculate the net charge and hydrophobicity index in order to  
247 estimate the molecule's viscosity and clearance<sup>2</sup>. According to Sharma et al., viscosity decreases with  
248 increasing variable fragment (Fv) net charge and increasing Fv charge symmetry parameter (FvCSP);  
249 however, the optimal Fv net charge in terms of drug clearance is between 0 and 6.2 with a  
250 CDRL1+CDRL3+CDRH3 hydrophobicity index sum (HI sum)  $< 4$ . Based on the wide range of values  
251 for these parameters in the  $3.1 \times 10^6$  predicted variants (Figure 6b, c), we filtered any sequences out  
252 that had a FvCSP  $< 6.61$  (trastuzumab FvCSP) or if they contained a Fv net charge  $> 6.2$ , and an HI  
253 sum  $> 4, < 0$ . This filtering criteria greatly reduced the sequence space down to  $4.02 \times 10^5$  variants. We  
254 next padded the CDRH3 sequences with 10 amino acids on the 5' and 3' ends and then ran these  
255 sequences through CamSol, a protein solubility predictor developed by Sormanni et al.<sup>30</sup>, which  
256 estimates and ranks sequence variants based on their theoretical solubility. The remaining variants  
257 produced a wide-range of protein solubility scores (Figure 6d) and sequences with a score  $< 0.5$   
258 (trastuzumab score) were filtered out, leaving 14,125 candidates for further analysis. As a last step in  
259 our *in silico* screening process, we aimed at reducing immunogenicity by predicting the peptide binding  
260 affinity of the variant sequences to MHC Class II molecules by utilizing NetMHCIIPan, a model  
261 previously developed by Jensen et al.<sup>31</sup>. One output from the model is a given peptide's % Rank of  
262 predicted affinity compared to a set of 200,000 random natural peptides. Typically, molecules with a %  
263 Rank  $< 2$  are considered strong binders and those with a % Rank  $< 10$  are considered weak binders to  
264 the MHC Class II molecules scanned. All possible 15-mers from the padded CDRH3 sequences were  
265 run through NetMHCIIPan. After predicting the affinities for a set of 26 HLA alleles determined to cover  
266 over 98% of the global population<sup>32</sup>, sequences were filtered out if any of the 15-mers contained a %  
267 Rank  $< 5.5$  (trastuzumab minimum % Rank) (Figure 6e). The number of 15-mers with a % Rank less  
268 than 10 and the average % Rank across all 15-mers for the remaining sequences were also calculated.  
269 Sequences with more than two 15-mers with a % Rank  $< 10$  (Figure 6f) and those with an average %  
270 Rank  $< 60.56$  (trastuzumab average % Rank) were also filtered out (Figure 6g). All remaining 4,881  
271 variants contain values equal to or greater than the parameters of the original trastuzumab sequence.  
272 When applying this same filtering scheme on the 11,300 experimentally determined binding sequences  
273 (obtained from training / test data), only 9 variants remained. Lastly, to determine the best developable  
274 sequences, we calculated an overall developability improvement score based on the mean of  
275 normalized values for each relevant parameter (see Materials and Methods), where trastuzumab would  
276 have a developability improvement score equal to 0. Of the remaining 4,881 predicted binding  
277 sequences, 293 variants were identified to have a higher developability score compared to the

Deep learning enables therapeutic antibody optimization in mammalian cells

278 maximum developability score of the 9 experimentally determined binding sequences (Figure 6h). The  
279 filtering parameters and number of remaining variants at each step for the *in silico* library are provided  
280 in Figure 6i.

281

282 **DISCUSSION**

283 Addressing the limitation of antibody optimization in mammalian cells, we have developed an approach  
284 based on deep learning that enables us to identify antigen-specific sequences with high precision.  
285 Calculating and predicting various biophysical properties of antigen-specific variants allows for efficient  
286 identification of the most developable antibody molecule, resulting in significant time and cost savings  
287 and greatly reducing risk for downstream clinical development. Using the clinically approved antibody  
288 trastuzumab, we performed single-site DMS followed by combinatorial mutagenesis to determine the  
289 antigen-binding landscape of CDRH3. This DMS-based mutagenesis strategy is crucial for attaining  
290 high quality training data that is enriched with antigen-binding variants, in this case nearly 10% of our  
291 library (Figure 2d). In contrast, if a completely randomized combinatorial mutagenesis strategy was  
292 employed (i.e., NNK degenerate codons), it would be unlikely to produce any significant fraction of  
293 antigen-binding variants. In the future, other approaches to mutagenesis that generate enriched training  
294 data<sup>33</sup>, such as shotgun scanning mutagenesis<sup>34</sup>, binary substitution<sup>35</sup> and recombination<sup>14,36</sup> may also  
295 be explored for training deep neural networks.

296 Our initial single-site DMS libraries screened for enriched mutations through antigen-binding, yet  
297 combining these mutations in a cohesive manner to alter biophysical properties while retaining high  
298 antigen affinity is challenging. The amino acid composition of binding and non-binding variants is highly  
299 similar (Figure 2e), and visually identifying the sequence patterns that lead to binding is a daunting, if  
300 not impossible task. Moreover, structure-based modeling was unable to discriminate between binders  
301 and non-binders as predicting fine-grained protein-complex affinities is highly challenging using  
302 generalistic methods such as Rosetta<sup>27</sup>. This is compounded by introducing CDRH3 loop mutations  
303 which likely result in challenging loop conformational changes<sup>37</sup>. While more advanced, ensemble-  
304 based ddG prediction methods<sup>38</sup> could result in better performance, applying this to millions of  
305 sequences may be infeasible, further exemplifying the value of deep neural networks that are able to  
306 learn the high-dimensional space of antigen-binding sequences.

307 A remarkable finding in this study was that experimental screening of a library of only  $5 \times 10^4$  variants,  
308 which reflected a tiny fraction (0.0054%) of the total sequence diversity of the DMS-based combinatorial  
309 mutagenesis library ( $7.17 \times 10^8$ ), was capable of training accurate neural networks. This suggests that  
310 physical library size limitations of mammalian expression systems (or other expression platforms such  
311 as phage and yeast) and deep sequencing read depth will not serve as a limitation for deep learning-  
312 guided protein engineering. Another important result was that deep sequencing of antigen-binding and  
313 non-binding populations showed nearly no observable difference in their positional amino acid usage  
314 (Figure 2e), revealing that neural networks are effectively capturing high-dimensional and non-linear  
315 patterns/interactions (Figure 5b).

*Deep learning enables therapeutic antibody optimization in mammalian cells*

316 In the current study, we selected LSTM-RNNs and CNNs as the basis of our classification models, as  
317 they represent two state of the art approaches in deep learning. Other machine learning approaches  
318 such as k-nearest neighbors, random forests, and support vector machines are also well-suited at  
319 identifying complex patterns from input data, but as data set sizes continue to grow, as is realizable  
320 with biological sequence data, deep neural networks tend to outperform these classical techniques<sup>17</sup>.  
321 Furthermore, deep generative modeling methods such as variational autoencoders and generative  
322 adversarial networks may also be used to explore the mutagenesis sequence space from directed  
323 evolution<sup>39</sup>.

324 We *in silico* generated approximately  $7.2 \times 10^7$  CDRH3 variants from DMS-based combinatorial  
325 diversity and used fully trained LSTM-RNN and CNN models to classify each sequence as a binder or  
326 non-binder. The  $7.2 \times 10^7$  sequence variants comprise only a subset of the potential sequence space  
327 and was chosen to minimize the computational effort, however, it still represents a library size several  
328 orders of magnitude greater than what is experimentally achievable in mammalian cells. We easily  
329 envision extending the screening capacity through script optimization and employing parallel computing  
330 on high performance clusters. Out of all variants classified, the LSTM-RNN and CNN predicted  
331 approximately 11-13% to bind the target antigen, showing exceptional agreement with the  
332 experimentally observed frequencies by flow cytometry (Figure 2d). In order to experimentally validate  
333 the precision of neural networks to predict antigen specificity, we randomly selected and expressed 30  
334 variants from the library of sequences with a minimum edit distance of 5 from trastuzumab. The  
335 precision of the LSTM-RNN and CNN models were each estimated to be ~85% (at  $P > 0.75$ ) according  
336 to predictions made on the test data sets (Figure 3b, d). By taking the consensus between models,  
337 however, we experimentally validated that all randomly selected (30/30) of the antigen-predicted  
338 sequences were indeed binders, and several of which were high affinity. While we anticipate false  
339 positives would be observed by increasing the sample size tested, validation of this subset strongly  
340 infers that potentially thousands of optimized lead candidates maintain a binding affinity in the range of  
341 therapeutic relevance, while also containing substantial sequence variability from the starting  
342 trastuzumab sequence. Future work to increase the stringency of selection during screening or a more  
343 detailed investigation of correlations between prediction probability and affinity could prove insightful  
344 towards retaining high target affinities. Experimentally validating the accuracy of the models to predict  
345 the binding status of sequence variants led us to take a more in depth look at the sequence space of  
346 predicted binding and non-binding variants. A sequence similarity network analysis at various LDs  
347 revealed no distinct clusters between binding and non-binding sequences, indicating an overall  
348 sequence similarity of both classifications. By then quantitatively analyzing neural network predictions,  
349 we were able to shed light on the high-dimensional patterns captured by the respective models and  
350 decipher amino acid combinations contributing to a sequence's classification.

351 Once an antibody's affinity for its target antigen is within a desirable range for efficacious biological  
352 modification, addressing other biophysical properties becomes the focus of antibody development. With  
353 recent advances in computational predictions<sup>40,41</sup>, a number of these properties, including viscosity,  
354 clearance, stability<sup>2</sup>, specificity<sup>42</sup>, solubility<sup>30</sup> and immunogenicity<sup>31</sup> can be approximated from sequence  
355 information alone. With the aim of selecting antibodies with improved characteristics, we subjected the

*Deep learning enables therapeutic antibody optimization in mammalian cells*

356 library of predicted binders to a number of these *in silico* approaches in order to provide a ranking  
357 structure and filtering strategy for developability (Figure 6). After implementing these methods to  
358 remove variants with a high likelihood of having poor viscosity, clearance or solubility, as well as those  
359 with high immunogenic potential, nearly 5,000 multi-parameter optimized antibody variants remained  
360 with developability scores greater than the original trastuzumab sequence. Although a limited number  
361 of developable sequences can be initially identified experimentally (Figure 6h), this only reflects a small  
362 fraction of the highly-developable sequence space (0.2%). By screening *in silico* libraries, the presence  
363 of every sequence variant within the defined space is guaranteed, ensuring the identification of globally  
364 optimized sequences. Future work to apply more stringent or additional filters which address other  
365 developability parameters (e.g. stability, specificity, humanization) could also be implemented to further  
366 reduce the sequence space down to the most developable therapeutic candidates across even more  
367 parameters. For instance, previous studies have investigated the likeness of therapeutic antibodies to  
368 the human antibody repertoire<sup>43</sup>. We also envision this approach to enable the optimization of other  
369 functional properties of therapeutic antibodies, such as pH-dependent antibody recycling<sup>44</sup> or  
370 affinity/avidity tuning<sup>45,46</sup>. Additionally, extending this approach to other regions across the variable light  
371 and heavy chain genes, namely other CDRs, may yield deep neural networks that are able to capture  
372 long-range, complex relationships between an antibody and its target antigen. To explore these patterns  
373 in greater depth, it may be useful to compare neural network predictions with other advanced structural  
374 modeling techniques such as ones that take advantage of geometric deep learning<sup>47</sup>.

375

## 376 METHODS

### 377 Mammalian cell culture and transfection

378 Hybridoma cells were cultured and maintained according to the protocols described by Mason et al.<sup>23</sup>.  
379 Hybridoma cells were electroporated with the 4D-Nucleofector™ System (Lonza) using the SF Cell Line  
380 4D-Nucleofector® X Kit L or X Kit S (Lonza, V4XC-2024, V4XC-2032) with the program CQ-104. Cells  
381 were prepared as follows: cells were isolated and centrifuged at 125 x G for 10 minutes, washed with  
382 Opti-MEM® I Reduced Serum Medium (Thermo, 31985-062), and centrifuged again with the same  
383 parameters. The cells were resuspended in SF buffer (per kit manufacturer guidelines), after which Alt-  
384 R gRNA (IDT) and ssODN donor (IDT) were added. All experiments performed utilize constitutive  
385 expression of Cas9 from *Streptococcus pyogenes* (SpCas9). Transfections of 1x10<sup>6</sup> and 1x10<sup>7</sup> cells  
386 were performed in 100 µl, single Nucleocuvettes™ with 0.575 or 2.88 nmol Alt-R gRNA and 0.5 or 2.5  
387 nmol ssODN donor respectively. Transfections of 2x10<sup>5</sup> cells were performed in 16-well, 20 µl  
388 Nucleocuvette™ strips with 115 pmol Alt-R gRNA and 100 pmol ssODN donor.

### 389 Flow cytometry analysis and sorting

390 Flow cytometry-based analysis and cell isolation were performed using the BD LSR Fortessa™ (BD  
391 Biosciences) and Sony SH800S (Sony), respectively. When labeling with fluorescently conjugated  
392 antigen or anti-IgG antibodies, cells were first washed with PBS, incubated with the labeling antibody  
393 and/or antigen for 30 minutes on ice, protected from light, washed again with PBS and then analyzed

*Deep learning enables therapeutic antibody optimization in mammalian cells*

394 or sorted. The labeling reagents and working concentrations are described in Supplementary Table 5.  
395 For cell numbers different from 10<sup>6</sup>, the antibody/antigen amount and incubation volume were adjusted  
396 proportionally.

397 **Sample preparation for deep sequencing**

398 Sample preparation for deep sequencing was performed similar to the antibody library generation  
399 protocol of the primer extension method described previously<sup>48</sup>. Genomic DNA was extracted from 1-  
400 5x10<sup>6</sup> cells using the Purelink™ Genomic DNA Mini Kit (Thermo, K182001). Extracted genomic DNA  
401 was subjected to a first PCR step. Amplification was performed using a forward primer binding to the  
402 beginning of the VH framework region and a reverse primer specific to the intronic region immediately  
403 3' of the J segment. PCRs were performed with Q5® High-Fidelity DNA polymerase (NEB, M0491L) in  
404 parallel reaction volumes of 50 ml with the following cycle conditions: 98°C for 30 seconds; 16 cycles  
405 of 98°C for 10 sec, 70°C for 20 sec, 72°C for 30 sec; final extension 72°C for 1 min; 4°C storage. PCR  
406 products were concentrated using DNA Clean and Concentrator (Zymo, D4013) followed by 0.8X  
407 SPRIselect (Beckman Coulter, B22318) left-sided size selection. Total PCR1 product was amplified in  
408 a PCR2 step, which added extension-specific full-length Illumina adapter sequences to the amplicon  
409 library. Individual samples were Illumina-indexed by choosing from 20 different index reverse primers.  
410 Cycle conditions were as follows: 98°C for 30 sec; 2 cycles of 98°C for 10 sec, 40°C for 20 sec, 72°C  
411 for 1 min; 6 cycles of 98°C for 10 sec, 65°C for 20 sec, 72°C for 1 min; 72°C for 5 min; 4°C storage.  
412 PCR2 products were concentrated again with DNA Clean and Concentrator and run on a 1% agarose  
413 gel. Bands of appropriate size (~550bp) were gel-purified using the Zymoclean™ Gel DNA Recovery  
414 kit (Zymo, D4008). Concentration of purified libraries were determined by a Nanodrop 2000c  
415 spectrophotometer and pooled at concentrations aimed at optimal read return. The quality of the final  
416 sequencing pool was verified on a fragment analyzer (Advanced Analytical Technologies) using DNF-  
417 473 Standard Sensitivity NGS fragment analysis kit. All samples passing quality control were  
418 sequenced. Antibody library pools were sequenced on the Illumina MiSeq platform using the reagent  
419 kit v3 (2x300 cycles, paired-end) with 10% PhiX control library. Base call quality of all samples was in  
420 the range of a mean Phred score of 34.

421 **Bioinformatics analysis and graphics**

422 The MiXCR v2.0.3 program was used to perform data pre-processing of raw FASTQ files<sup>49</sup>. Sequences  
423 were aligned to a custom germline gene reference database containing the known sequence  
424 information of the V- and J-gene regions for the variable heavy chain of the trastuzumab antibody gene.  
425 Clonotype formation by CDRH3 and error correction were performed as described by Bolotin et al<sup>49</sup>.  
426 Functional clonotypes were discarded if: 1) a duplicate CDRH3 amino acid sequence arising from  
427 MiXCR uncorrected PCR errors, or 2) a clone count equal to one. Downstream analysis was performed  
428 using R v3.2.2<sup>50</sup> and Python v3.6.5<sup>51</sup>. Graphics were generated using the R packages ggplot2<sup>52</sup>,  
429 RColorBrewer<sup>53</sup>, and ggseqlogo<sup>54</sup>.

Deep learning enables therapeutic antibody optimization in mammalian cells

#### 430 **Calculation of enrichment ratios (ERs) in DMS**

431 The ERs of a given variant was calculated according to previous methods<sup>55</sup>. Clonal frequencies of  
432 variants enriched for antigen specificity by FACS,  $f_{i,Ag+}$ , were divided by the clonal frequencies of the  
433 variants present in the original library,  $f_{i,Ab+}$ , according to Equation 1.

$$434 \quad ER = \frac{f_{i,Ag+}}{f_{i,Ab+}}$$

435 (Eq. 1)

436 A minimum value of -2 was designated to variants with log[ER] values less than or equal -2 and variants  
437 not present in the dataset were disregarded in the calculation. A clone was defined based on the exact  
438 a.a. sequence of the CDRH3.

#### 439 **Redesign of trastuzumab in Rosetta for diversity of sequences**

440 The Rosetta program<sup>27</sup> was used to redesign the trastuzumab antibody in complex with the extracellular  
441 domain of HER2 (PDB id: 1N8Z)<sup>25</sup>. Ten residues in the CDRH3 loop of trastuzumab (residues 98-108  
442 of the heavy chain) were allowed to mutate to any natural amino acid, while all other residues were  
443 allowed to change rotameric conformation. A RosettaScript invoked the PackRotamersMover, a  
444 stochastic MonteCarlo algorithm, to optimize the sequence of the antibody to CDRH3 according to the  
445 Rosetta energy function, followed by backbone minimization. Energies were computed using Rosetta's  
446 ddG filter. Rosetta was run to generate 5000 sequences stochastically, and this resulted in 48  
447 sequences. Rosetta's output files were processed using RS-Toolbox<sup>56</sup>.

#### 448 **Classification of experimentally-determined sequences in Rosetta**

449 Each of the 11,300 binding and 27,539 non-binding sequences from the combinatorial library were  
450 modelled in Rosetta<sup>27</sup>. For each experimentally-determined binding or non-binding sequence, the  
451 structure of the HER2:trastuzumab complex was used as input and the residues diverging from the  
452 wildtype were mutated using the PackRotamersMover in RosettaScripts<sup>57</sup>. The backbone and the side  
453 chains were minimized with Rosetta's MinMover after the sequence was modeled to optimized intra-  
454 and inter-chain contacts. Rosetta's predicted interface score (ddG) was used as the relative  
455 classification score.

#### 456 **Codon selection for rational library design**

457 Codon selection for rational library design was based off the equation provided by Mason et al.<sup>23</sup>,  
458 (Equation 2), where  $Y_{n,deg}$  represents the amino acid frequency for a given degenerate codon scheme,  
459  $Y_{n,target}$  is the target amino acid frequency, and  $n$  is the number of amino acids, 20. Residues identified  
460 in DMS analysis to have a positive enrichment ( $ER > 1$ , or  $\log[ER] > 0$ ) were normalized according to  
461 their enrichment ratios and were converted to theoretical frequencies and taken as the target amino  
462 acid frequencies. Degenerate codon schemes were then selected which most closely reflect these  
463 frequencies as calculated by the mean squared error between the degenerate codon and the target  
464 frequencies.

*Deep learning enables therapeutic antibody optimization in mammalian cells*

465           
$$\text{Optimal Codon} = \arg_{x} \min \left( \frac{1}{n} \sum_{i=1}^n (Y_{n,\text{deg}} - Y_{n,\text{target}})^2 \right)$$

466       (Eq. 2)

467       In certain instances, if the selected degenerate codon did not represent desirable amino acid  
468       frequencies or contained undesirable amino acids, a mixture of degenerate codons were selected and  
469       pooled together to achieve better coverage of the functional sequence space.

470       **Deep learning model construction**

471       Machine learning models were built in Python v3.6.5. LSTM-RNNs, and CNNs were built using the  
472       Keras<sup>58</sup> v2.1.6 Sequential model as a wrapper for TensorFlow<sup>59</sup> v1.8.0. Model architecture and  
473       hyperparameters were optimized by performing a grid search of relevant variables for a given model.  
474       These variables include nodes per layer, activation function(s), optimizer, loss function, dropout rate,  
475       batch size, number of epochs, number of filters, kernel size, stride length, and pool size. Grid searches  
476       were performed by implementing a k-fold cross validation of the data set.

477       **Deep learning model training and testing**

478       Data sets for antibody expressing, non-binding, and binding sequences (Sequencing statistics:  
479       Supplementary Tables 1, 2) were aggregated to form a single, binding/non-binding data set where  
480       antibody expressing sequences were classified as non-binders, unless also identified among the  
481       binding sequences. Sequences from one round of antigen enrichment were excluded from the training  
482       data set. The complete, aggregated data set was then randomly arranged and appropriate class labeled  
483       sequences were removed to achieve the desired classification ratio of binders to non-binders (50/50,  
484       20/80, 10/90, and non-adjusted). The class adjusted data set was further split into a training set (70%),  
485       and two testing sets (15% each), where one test set reflected the classification ratio observed for  
486       training and the other reflected a classification ratio of approximately 10/90 to resemble the  
487       physiological expected frequency of binders.

488       **Sequence similarity and model attribution analysis of predicted variants**

489       Sequence similarity networks of sequences predicted to be antigen positive and antigen negative were  
490       constructed for Levenshtein Distance 1-6 were constructed using the igraph R package<sup>60</sup> v1.2.4. The  
491       resulting networks were analyzed with respect to their overall connectivity, the composition of their  
492       largest clusters and the overall degree distribution between the classes.

493       The Integrated Gradients technique<sup>29</sup> was used to assess the relative attribution of each feature of a  
494       given input sequence towards the final prediction score. First, a baseline was obtained by zeroing out  
495       the input vector and the path integral of the gradients from baseline to the input vector was then  
496       approximated with a step size of 100. Integrated gradients were visualized as sequence logos.  
497       Sequence logos were created by the python module Logomaker<sup>61</sup>.

Deep learning enables therapeutic antibody optimization in mammalian cells

498 **In silico sequence classification and sequence parameters**

499 All possible combinations of amino acids present in the DMS-based combinatorial mutagenesis libraries  
500 were used to calculate the total theoretical sequence space of  $7.17 \times 10^8$ .  $7.2 \times 10^7$  sequence variants  
501 were generated *in silico* by taking all possible combinations of the amino acids used per position in the  
502 combinatorial mutagenesis library designed from the DMS data following three rounds of enrichment  
503 for antigen binding variants (Supplementary Fig. 2c, 3c); Alanine was also selected to be included at  
504 position 103. All *in silico* sequences were then classified as a binder or non-binder by the trained LSTM-  
505 RNN and CNN models. Sequences were selected for further analysis if they were classified in both  
506 models with a prediction probability ( $P$ ) of more than 0.75.

507 The Fv net charge and Fv charge symmetry parameter (FvCSP) were calculated as described by  
508 Sharma et al. Briefly, the net charge was determined by first solving the Henderson-Hasselbalch  
509 equation for each residue at a specified pH (here 5.5) with known amino acid pKas<sup>62</sup>. The sum across  
510 all residues for both the VL and VH was then calculated as the Fv net charge. The FvCSP was  
511 calculated by taking the product of the VL and VH net charges. The hydrophobicity index (HI) was also  
512 calculated as described by Sharma et al., according to the following equation:  $HI = -(\sum n_i E_i / \sum n_j E_j)$ . E  
513 represents the Eisenberg value of an amino acid, n is the number of an amino acid, and i and j are  
514 hydrophobic and hydrophilic residues respectively.

515 The protein solubility score was determined for each, full-length CDRH3 sequence (15 a.a.) padded  
516 with 10 amino acids on both the 5' and 3' ends (35 a.a.) by the CamSol method<sup>30</sup> at pH 7.0.

517 The binding affinities for a reference set of 26 HLA alleles<sup>32</sup> were determined for each 15-mer contained  
518 within the 10 amino acid padded CDRH3 sequence (35 a.a.) by NetMHCIIpan 3.2<sup>31</sup>. The output provides  
519 for each 15-mer a predicted affinity in nM and the % Rank which reflects the 15-mer's affinity compared  
520 to a set of random natural peptides. The % Rank measure is unaffected by the bias of certain molecules  
521 against stronger or weaker affinities and is used to classify peptides as weak or strong binders towards  
522 the specified MHC Class II allele. The minimum % Rank, the number of 15-mers with % Rank less than  
523 10 (classification of weak binder), and the average % Rank were calculated across all 21 15-mers for  
524 a single CDRH3 sequence across all 26 HLA alleles.

525 Overall developability improvement of the antibody sequences was determined by first normalizing the  
526 FvCSP, CamSol score, and average NetMHCII % Rank according to the range of values observed in  
527 the remaining sequences post-filtering. The normalized CamSol protein solubility score was then  
528 weighted by a factor of 2 for its importance in determining developability. Lastly, the mean across these  
529 three parameters was taken to produce the overall developability improvement score. Since the  
530 sequences were filtered with the calculated values for trastuzumab, trastuzumab would have an overall  
531 developability improvement equal to 0.

Deep learning enables therapeutic antibody optimization in mammalian cells

532        *Overall developability*

$$533 \quad = \frac{1}{3} \left( \left( \frac{FvCSP - \min(FvCSP)}{\max(FvCSP) - \min(FvCSP)} \right) + 2 * \left( \frac{CamSol - \min(CamSol)}{\max(CamSol) - \min(CamSol)} \right) \right. \\ 534 \quad \left. + \left( \frac{avgNetMHC - \min(avgNetMHC)}{\max(avgNetMHC) - \min(avgNetMHC)} \right) \right)$$

535        (Eq. 3)

536        **Affinity measurements by biolayer interferometry**

537        Monoclonal populations of the individual variants were isolated by performing a single-cell sort.  
538        Following expansion, supernatant for all variants was collected and filtered through a 0.20 µm filter  
539        (Sartorius, 16534-K). Affinity measurements were then performed on an Octet RED96e (FortéBio) with  
540        the following parameters. Anti-human capture sensors (FortéBio, 18-5060) were hydrated in  
541        conditioned media diluted 1 in 2 with kinetics buffer (FortéBio, 18-1105) for at least 10 minutes before  
542        conditioning through 4 cycles of regeneration consisting of 10 seconds incubation in 10 mM glycine, pH  
543        1.52 and 10 seconds in kinetics buffer. Conditioned sensors were then loaded with 0 µg/mL (reference  
544        sensor), 10 µg/mL trastuzumab (reference sample), or hybridoma supernatant (approximately 20  
545        µg/mL) diluted 1 in 2 with kinetics buffer followed by blocking with mouse IgG (Rockland, 010-0102) at  
546        50 µg/mL in kinetics buffer. After blocking, loaded sensors were equilibrated in kinetics buffer and  
547        incubated with either 5 nM or 25 nM HER2 protein (Sigma-aldrich, SRP6405-50UG). Lastly, sensors  
548        were incubated kinetics buffer to allow antigen dissociation. Kinetics analysis was performed in analysis  
549        software Data Analysis HT v11.0.0.50.

550

551        **ACKNOWLEDGEMENTS**

552        We acknowledge the ETH Zurich D-BSSE Single Cell Unit and the ETH Zurich D-BSSE Genomics  
553        Facility for support, in particular, M. Di Tacchio, A. Gumienny, E. Burcklen, and C. Beisel. We also thank  
554        the Vendruscolo Lab (Cambridge, UK), in particular P. Sormanni, for assistance with implementing the  
555        CamSol method on large libraries, as well as the group of Prof. Morten Nielson (DTU, Denmark) for  
556        providing an easy-to-use package for MHC Class II affinity predictions. Funding was provided by the  
557        National Competence Center for Research on Molecular Systems Engineering.

558

559        **AUTHOR CONTRIBUTIONS**

560        D.M.M., S.F., C.R.W. and S.T.R. developed the methodology; D.M.M. and S.T.R. designed the  
561        experiments and wrote the manuscript; D.M.M., C.R.W. and S.F. analyzed sequencing data and  
562        performed deep learning analysis; P.G. and B.E.C. designed and performed structural modelling  
563        experiments and analysis; C.J. generated in silico libraries; D.M.M. performed experiments; B.W., and  
564        S.M.M. performed cell line development.

565

Deep learning enables therapeutic antibody optimization in mammalian cells

566 COMPETING INTERESTS

567 ETH Zurich has filed for patent protection on the technology described herein, and D.M.M., S.F.,  
568 C.R.W., and S.T.R. are named as co-inventors on this patent (United States Patent and Trademark  
569 Office Provisional Application: 62/831,663).

570

571 REFERENCES

- 572 1. Paul, S. M. *et al.* How to improve R&D productivity: the pharmaceutical industry's grand challenge.  
573 *Nat. Rev. Drug Discov.* **9**, 203–214 (2010).
- 574 2. Sharma, V. K. *et al.* In silico selection of therapeutic antibodies for development: Viscosity,  
575 clearance, and chemical stability. *Proc. Natl. Acad. Sci.* **111**, 18601–18606 (2014).
- 576 3. Jain, T. *et al.* Biophysical properties of the clinical-stage antibody landscape. *Proc. Natl. Acad. Sci.*  
577 **114**, 944–949 (2017).
- 578 4. Hu, D. *et al.* Effective Optimization of Antibody Affinity by Phage Display Integrated with High-  
579 Throughput DNA Synthesis and Sequencing Technologies. *PLOS ONE* **10**, e0129125 (2015).
- 580 5. Bos, A. B. *et al.* Development of a semi-automated high throughput transient transfection system.  
581 *J. Biotechnol.* **180**, 10–16 (2014).
- 582 6. Tomar, D. S., Kumar, S., Singh, S. K., Goswami, S. & Li, L. Molecular basis of high viscosity in  
583 concentrated antibody solutions: Strategies for high concentration drug product development.  
584 *mAbs* **8**, 216–228 (2016).
- 585 7. Roth, E. M. *et al.* Antidrug Antibodies in Patients Treated with Alirocumab. *N. Engl. J. Med.* **376**,  
586 1589–1590 (2017).
- 587 8. Greiff, V. *et al.* Learning the High-Dimensional Immunogenomic Features That Predict Public and  
588 Private Antibody Repertoires. *J. Immunol.* ji1700594 (2017). doi:10.4049/jimmunol.1700594
- 589 9. Christensen, T., Frandsen, A., Glazier, S., Humpherys, J. & Kartchner, D. Machine Learning  
590 Methods for Disease Prediction with Claims Data. in *2018 IEEE International Conference on*  
591 *Healthcare Informatics (ICHI)* 467–4674 (2018). doi:10.1109/ICHI.2018.00108
- 592 10. Packer, M. S. & Liu, D. R. Methods for the directed evolution of proteins. *Nat. Rev. Genet.* **16**, 379–  
593 394 (2015).
- 594 11. Fox, R. *et al.* Optimizing the search algorithm for protein engineering by directed evolution. *Protein*  
595 *Eng. Des. Sel.* **16**, 589–597 (2003).

Deep learning enables therapeutic antibody optimization in mammalian cells

- 596 12. Fox, R. Directed molecular evolution by machine learning and the influence of nonlinear  
597 interactions. *J. Theor. Biol.* **234**, 187–199 (2005).
- 598 13. Romero, P. A., Krause, A. & Arnold, F. H. Navigating the protein fitness landscape with Gaussian  
599 processes. *Proc. Natl. Acad. Sci.* **110**, E193–E201 (2013).
- 600 14. Bedbrook, C. N., Yang, K. K., Rice, A. J., Grdinaru, V. & Arnold, F. H. Machine learning to design  
601 integral membrane channelrhodopsins for efficient eukaryotic expression and plasma membrane  
602 localization. *PLOS Comput. Biol.* **13**, e1005786 (2017).
- 603 15. Angermueller, C., Pärnamaa, T., Parts, L. & Stegle, O. Deep learning for computational biology.  
604 *Mol. Syst. Biol.* **12**, 878 (2016).
- 605 16. Wainberg, M., Merico, D., Delong, A. & Frey, B. J. Deep learning in biomedicine. *Nat. Biotechnol.*  
606 **36**, 829–838 (2018).
- 607 17. Alipanahi, B., Delong, A., Weirauch, M. T. & Frey, B. J. Predicting the sequence specificities of  
608 DNA- and RNA-binding proteins by deep learning. *Nat. Biotechnol.* **33**, 831–838 (2015).
- 609 18. Cuperus, J. T. *et al.* Deep learning of the regulatory grammar of yeast 5' untranslated regions from  
610 500,000 random sequences. *Genome Res.* (2017). doi:10.1101/gr.224964.117
- 611 19. Bulik-Sullivan, B. *et al.* Deep learning using tumor HLA peptide mass spectrometry datasets  
612 improves neoantigen identification. *Nat. Biotechnol.* **37**, 55–63 (2019).
- 613 20. LeCun, Y., Bengio, Y. & Hinton, G. Deep learning. *Nature* **521**, 436–444 (2015).
- 614 21. Rosenblatt, F. The Perceptron, a Perceiving and Recognizing Automation. (1957).
- 615 22. Pogson, M., Parola, C., Kelton, W. J., Heuberger, P. & Reddy, S. T. Immunogenomic engineering  
616 of a plug-and-(dis)play hybridoma platform. *Nat. Commun.* **7**, 12535 (2016).
- 617 23. Mason, D. M. *et al.* High-throughput antibody engineering in mammalian cells by CRISPR/Cas9-  
618 mediated homology-directed mutagenesis. *Nucleic Acids Res.* (2018). doi:10.1093/nar/gky550
- 619 24. Whitehead, T. A. *et al.* Optimization of affinity, specificity and function of designed influenza  
620 inhibitors using deep sequencing. *Nat. Biotechnol.* **30**, 543 (2012).
- 621 25. Cho, H.-S. *et al.* Structure of the extracellular region of HER2 alone and in complex with the  
622 Herceptin Fab. *Nature* **421**, 756–760 (2003).
- 623 26. Rose, A. S. *et al.* NGL viewer: web-based molecular graphics for large complexes. *Bioinformatics*  
624 **34**, 3755–3758 (2018).

Deep learning enables therapeutic antibody optimization in mammalian cells


- 625 27. Leaver-Fay, A. *et al.* Chapter nineteen - Rosetta3: An Object-Oriented Software Suite for the  
626 Simulation and Design of Macromolecules. in *Methods in Enzymology* (eds. Johnson, M. L. &  
627 Brand, L.) **487**, 545–574 (Academic Press, 2011).
- 628 28. Miho, E., Roškar, R., Greiff, V. & Reddy, S. T. Large-scale network analysis reveals the sequence  
629 space architecture of antibody repertoires. *Nat. Commun.* **10**, 1321 (2019).
- 630 29. Sundararajan, M., Taly, A. & Yan, Q. Axiomatic Attribution for Deep Networks. *ArXiv170301365 Cs*  
631 (2017).
- 632 30. Sormanni, P., Aprile, F. A. & Vendruscolo, M. The CamSol Method of Rational Design of Protein  
633 Mutants with Enhanced Solubility. *J. Mol. Biol.* **427**, 478–490 (2015).
- 634 31. Jensen, K. K. *et al.* Improved methods for predicting peptide binding affinity to MHC class II  
635 molecules. *Immunology* **154**, 394–406 (2018).
- 636 32. Greenbaum, J. *et al.* Functional classification of class II human leukocyte antigen (HLA) molecules  
637 reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes.  
638 *Immunogenetics* **63**, 325–335 (2011).
- 639 33. Wu, Z., Kan, S. B. J., Lewis, R. D., Wittmann, B. J. & Arnold, F. H. Machine learning-assisted  
640 directed protein evolution with combinatorial libraries. *Proc. Natl. Acad. Sci.* **201901979** (2019).  
641 doi:10.1073/pnas.1901979116
- 642 34. Vajdos, F. F. *et al.* Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2  
643 Antibody Obtained with Shotgun Scanning Mutagenesis. *J. Mol. Biol.* **320**, 415–428 (2002).
- 644 35. Townsend, S. *et al.* Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization  
645 of therapeutic antibodies. *Proc. Natl. Acad. Sci.* **112**, 15354–15359 (2015).
- 646 36. Trudeau, D. L., Smith, M. A. & Arnold, F. H. Innovation by homologous recombination. *Curr. Opin.*  
647 *Chem. Biol.* **17**, 902–909 (2013).
- 648 37. Weitzner, B. D. *et al.* Modeling and docking of antibody structures with Rosetta. *Nat. Protoc.* **12**,  
649 401–416 (2017).
- 650 38. Barlow, K. A. *et al.* Flex ddG: Rosetta Ensemble-Based Estimation of Changes in Protein–Protein  
651 Binding Affinity upon Mutation. *J. Phys. Chem. B* **122**, 5389–5399 (2018).
- 652 39. Riesselman, A. J., Ingraham, J. B. & Marks, D. S. Deep generative models of genetic variation  
653 capture the effects of mutations. *Nat. Methods* **15**, 816–822 (2018).

Deep learning enables therapeutic antibody optimization in mammalian cells

- 654 40. Sormanni, P., Aprile, F. A. & Vendruscolo, M. Third generation antibody discovery methods: in  
655 silico rational design. *Chem. Soc. Rev.* **47**, 9137–9157 (2018).
- 656 41. Raybould, M. I. J. et al. Five computational developability guidelines for therapeutic antibody  
657 profiling. *Proc. Natl. Acad. Sci.* **116**, 4025–4030 (2019).
- 658 42. Rabia, L. A., Zhang, Y., Ludwig, S. D., Julian, M. C. & Tessier, P. M. Net charge of antibody  
659 complementarity-determining regions is a key predictor of specificity. *Protein Eng. Des. Sel.* (2019).  
660 doi:10.1093/protein/gzz002
- 661 43. Abhinandan, K. R. & Martin, A. C. R. Analyzing the “Degree of Humanness” of Antibody  
662 Sequences. *J. Mol. Biol.* **369**, 852–862 (2007).
- 663 44. Igawa, T. et al. Antibody recycling by engineered pH-dependent antigen binding improves the  
664 duration of antigen neutralization. *Nat. Biotechnol.* **28**, 1203–1207 (2010).
- 665 45. Kang, J. C. et al. Engineering a HER2-specific antibody–drug conjugate to increase lysosomal  
666 delivery and therapeutic efficacy. *Nat. Biotechnol.* **1** (2019). doi:10.1038/s41587-019-0073-7
- 667 46. Slaga, D. et al. Avidity-based binding to HER2 results in selective killing of HER2-overexpressing  
668 cells by anti-HER2/CD3. *Sci. Transl. Med.* **10**, eaat5775 (2018).
- 669 47. Gainza, P. et al. Deciphering interaction fingerprints from protein molecular surfaces. *bioRxiv*  
670 606202 (2019). doi:10.1101/606202
- 671 48. Menzel, U. et al. Comprehensive Evaluation and Optimization of Amplicon Library Preparation  
672 Methods for High-Throughput Antibody Sequencing. *PLoS ONE* **9**, e96727 (2014).
- 673 49. Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. *Nat. Methods*  
674 **12**, 380–381 (2015).
- 675 50. R. Development Core Team. *R: A Language and Environment for Statistical Computing*. (R  
676 Foundation for Statistical Computing).
- 677 51. van Rossum, G. & Drake, F. L. *The Python Language Reference Manual*. (Network Theory Ltd.,  
678 2011).
- 679 52. Wickham, H. *ggplot2: Elegant Graphics for Data Analysis*. (Springer International Publishing,  
680 2016).
- 681 53. Brewer, C. A., Hatchard, G. W. & Harrower, M. A. ColorBrewer in Print: A Catalog of Color Schemes  
682 for Maps. *Cartogr. Geogr. Inf. Sci.* **30**, 5–32 (2003).


Deep learning enables therapeutic antibody optimization in mammalian cells

- 683 54. Wagih, O. ggseqlogo: a versatile R package for drawing sequence logos. *Bioinformatics* **33**, 3645–  
684 3647 (2017).
- 685 55. Fowler, D. M. *et al.* High-resolution mapping of protein sequence-function relationships. *Nat.*  
686 *Methods* **7**, 741 (2010).
- 687 56. Bonet, J., Harteveld, Z., Sesterhenn, F., Scheck, A. & Correia, B. E. rstoobox - a Python library for  
688 large-scale analysis of computational protein design data and structural bioinformatics. *BMC*  
689 *Bioinformatics* **20**, 240 (2019).
- 690 57. Fleishman, S. J. *et al.* RosettaScripts: A Scripting Language Interface to the Rosetta  
691 Macromolecular Modeling Suite. *PLOS ONE* **6**, e20161 (2011).
- 692 58. Chollet, F. Keras. (2015). Available at: <https://keras.io/>. (Accessed: 24th April 2019)
- 693 59. Abadi, M. *et al.* TensorFlow: A System for Large-scale Machine Learning. in *Proceedings of the*  
694 *12th USENIX Conference on Operating Systems Design and Implementation* 265–283 (USENIX  
695 Association, 2016).
- 696 60. Csárdi, G. & Nepusz, T. The igraph software package for complex network research. in (2006).
- 697 61. Tareen, A. & Kinney, J. B. Logomaker: Beautiful sequence logos in python. *bioRxiv* 635029 (2019).  
698 doi:10.1101/635029
- 699 62. Kline, P. Amino Acid pKa Values and Side Chain Identities. (2006). Available at:  
700 [http://homepage.smc.edu/kline\\_peggy/Organic/Amino\\_Acid\\_pKa.pdf](http://homepage.smc.edu/kline_peggy/Organic/Amino_Acid_pKa.pdf). (Accessed: 24th April 2019)



**Figure 1: Implementing deep learning to predict antibody target specificity**

**(a)** Generating quality data capable of training accurate models. First, deep mutational scanning assesses the impact mutations have on protein function across many different positions. These insights can then be applied to combinatorial mutagenesis strategies to guide protein library design capable of producing thousands of binding variants. **(b)** Sequence information for binders and non-binders can then be used to train deep neural networks to accurately predict antigen specificity of unknown antibody variants, producing millions of predicted binders. These binders can then be subjected to any available in silico methods for predicted various developability attributes.



**Figure 2: Sequence and structure-based analysis of the mutational landscape**

**(a)** Flow cytometry profile following integration of tiled mutations by homology-directed mutagenesis. Antigen specific variants underwent 3 rounds of enrichment

er (S) this present (which was) (b) Corresponding


int in perpetuity. It is made heatmap (left) following sequencing

analysis of the pre-sorted (Ab+) and post-sorted (Ag+) populations (Supplementary Table 1). Wild type amino acids are marked by black circles. The resulting sequence logo plot (right) generated by positively enriched mutations per position. **(c)** 3D protein structure of trastuzumab in complex with its target antigen, HER2<sup>25,26</sup> (left).

Locations of surface exposed residues: 102D, 103G, 104F, and 105Y are given. The protein design program Rosetta was run 5,000 times to generate sequence variants of trastuzumab predicted to bind the antigen HER2. The resulting sequence logo plot of the 48 generated CDRH3 loops (right) differs substantially from the DMS-based sequence logo plot. (d)

Combinatorial mutagenesis libraries are designed from enrichment ratios observed in DMS data and integrated into the trastuzumab variant by homology-directed mutagenesis. Flow cytometry plots resulting from transfection of the rationally designed library. Deep sequencing was performed on the library (Ab+), non-binding variants (Ag-), and binding variants after 1 and 2 rounds of enrichment (Ag+1, Ag+2) (Supplementary Fig. 3, Supplementary




Table 2). **(e)** Amino acid frequency plots of antigen binding and non-binding variants reveals nearly indistinguishable amino acid usages across all positions. **(f)** Distribution plot for the predicted Rosetta ddG scores for each sequence in the experimentally determined binding population (11,300 binders, shown in blue) and non-binding population (27,539 non-binders, shown in red) (left). The distribution plot is normalized for comparison purposes. Receiver operating characteristic (ROC) curve with area under curve (AUC) using the Rosetta ddG score to predict binding and non-binding variants shows poor classification (right).

**a**

**Figure 3: Deep learning models accurately predict antigen specificity**


The selected network architectures and their model performance curves for classification of binding and non-binding sequences. Model training was performed on 70% of the data and testing was performed by withholding the remaining 30% and then comparing the model's classification of test sequences with the known classification. In lieu of adjusting the data set to a defined class split of binding/non-binding sequences, all known information was utilized to train and test the networks (approx. class split of 31%).

**(a)** LSTM-RNN architecture and parameters used for model fitting. **(b)** ROC (receiver operating character) curve and PR (precision-recall) curve observed on the classification of sequences in the test set by the LSTM-RNN. **(c)** CNN architecture and parameters used for model fitting. **(d)** ROC curve and PR curve observed on the classification of sequences in the test set by the CNN. The high values observed for the ROC area under curve (AUC) and average precision of both networks represent robust measures of model accuracy and precision.

**b****c****d**


**a**



Variant	CDRH3 Sequence	RNN P(Binder)	CNN P(Binder)	LD	$K_p$ (nM)	$k_a$ (1/Ms)	$k_d$ (1/s)
1	WQEAAYAH	0.833	0.930	5	3.31	2.2E+05	7.3E-04
2	YGGGRGMYQLE	0.906	0.973	6	1.74	2.9E+05	5.0E-04
3	WNQLGMYVND	0.874	0.888	6	3.36	2.2E+05	7.5E-04
4	YGMRLGLYAYE	0.942	0.948	6	1.47	3.1E+05	4.6E-04
5	WMETGFYTHD	0.895	0.966	5	0.14	1.1E+05	1.4E-05
6	WNAPSFYAND	0.885	0.977	5	7.43	3.0E+05	2.2E-03
7	WQQIGLYELD	0.942	0.889	5	3.20	1.9E+05	6.2E-04
8	WAMILGMYAH	0.847	0.779	5	2.32	3.0E+05	7.0E-04
9	YQANGLYAYE	0.959	0.909	7	0.77	4.3E+05	4.2E-03
10	YGGGRGMYQLE	0.906	0.973	6	1.74	2.9E+05	5.0E-04
11	WAPYGLYAH	0.948	0.959	5	1.28	2.9E+05	3.7E-04
12	WDGPAPFYELD	0.860	0.936	5	31.1	1.0E+05	3.2E-03
13	WGIHSFYEH	0.844	0.869	5	0.54	1.8E+05	9.6E-05
14	YGEYGMVYVN	0.888	0.870	7	1.24	3.2E+05	4.0E-04
15	WRDRGFYED	0.858	0.974	5	0.71	2.6E+05	1.9E-04
16	WEEYGLYVHD	0.933	0.992	6	1.98	7.8E+04	1.5E-04
17	YASAGMYTHD	0.927	0.883	7	4.92	3.4E+05	1.7E-03
18	YGDAGMYALK	0.973	0.995	6	4.84	3.7E+05	1.8E-03
19	WQLGGMYTHD	0.919	0.941	6	7.55	1.6E+05	1.2E-03
20	WNSDGLYAYE	0.864	0.961	5	7.22	3.3E+05	2.4E-03
21	WQRGGFYVND	0.956	0.993	5	0.51	2.5E+05	1.3E-04
22	YGARGFYQND	0.892	0.789	5	6.33	4.4E+05	2.8E-03
23	YAGPGMYTNQ	0.870	0.830	7	3.37	2.4E+05	8.2E-04
24	WNPHGLYVND	0.939	0.974	6	1.11	2.4E+05	2.7E-04
25	YGSNGLYANQ	0.914	0.908	6	7.25	3.1E+05	2.3E-03
26	WPKVGLYTNQ	0.853	0.865	6	2.46	2.6E+05	6.3E-04
27	WGIVSFYEND	0.871	0.873	5	3.90	2.0E+05	8.0E-04
28	YSMPGMYTNA	0.848	0.938	8	3.60	2.6E+05	9.5E-04
29	WAEAGMYEFD	0.880	0.915	6	3.60	1.3E+05	4.5E-04
30	WPMCGMYTHD	0.835	0.855	6	3.86	1.1E+05	4.4E-04
Trastuzumab	WGGDGFYAMD	0.962	0.938	0	0.40	2.5E+05	1.0E-04

**b**

**Figure 4: Deep neural network predicted sequences are experimentally validated to be antigen-specific**


**(a)** To test the precision of the neural network predictions, 30 variants were randomly selected after increasing the prediction threshold ( $P(\text{binder}) > 0.75$ ) and taking the consensus sequences between the LSTM-RNN and CNN. These sequences were integrated into individual hybridoma cells lines by separately transfecting ssODN donor sequences with gRNA. **(b)** Affinities for the 30 variant sequences were determined by biolayer interferometry (BLI). Although most sequences display a minor decrease in affinity for the target antigen, the majority of sequences still exude affinities of therapeutic relevance in the single nanomolar (24/30) or sub-nanomolar range (5/30). **(c)** Iso-affinity graph of the variant sequences.

**c**

**a****b**

**Figure 5: Deep neural networks decipher non-linear interactions to accurately classify binding and non-binding sequences**

**(a)** A sequence similarity network analysis was completed on 5,000 randomly selected predicted binding (blue) and 5,000 non-binding variants (black) to investigate potential sequence similarities of the classification choices (left). Clustering was performed at a Levenshtein distance ( $LD \leq 2$ ); Similarity network analyses performed with additional  $LDs$  can be found in Supplementary Table 4 and Supplementary Fig. 12. Although the largest cluster within the network (middle) contains 90% predicted binding variants, this comprises only 30% of all sequences in the network. Conversely, 42% of sequences do not cluster with any other neighboring sequences, thereby revealing that for the majority of variants, there are no discernible clusters of binding or non-binding predictions. **(b)** The Integrated Gradients method efficiently extracts and enables visualization of the classification patterns established by the LSTM-RNN (left) and the CNN (right). For the specific example, variants identified in the network with a  $LD$  of only 2 were classified as binding and non-binding sequences respectively. The LSTM-RNN and CNN uniquely identify non-linear combinations of amino acids that contribute to its classification as a binder (highlighted in green) or its classification as a non-binder (highlighted in red).



**Figure 6: In silico screening of predicted binders identifies globally optimized variants**

Antigen specific variants result in a wide range of *in silico* calculated parameters for developability. The following are staggered histograms showing the parameter distributions of all deep learning (DL)-predicted binders (light) and the experimentally observed binders (dark) at the different stages of filtering. Red boxes indicate filtering cut-offs determined by the developability metric calculated for the original trastuzumab sequence. **(a)** Levenshtein distance from wild-type trastuzumab. **(b)** Net charge of the VH domain. **(c)** CDRH3 hydrophobicity index. **(d)** CamSol intrinsic solubility score. **(e)** The minimum NetMHCIIpan % Rank (< 2 ~ strong affinity; < 10 ~ weak affinity) across all possible 15-mers for a given CDRH3 sequence and across all HLA alleles. **(f)** The number of 15-mers found within a given CDRH3 sequence that have a % Rank < 10 across all alleles. **(g)** The average NetMHCIIpan % Rank across all possible 15-mers and HLA alleles. **(h)** Scatter/violin plot for the overall developability improvement score (Eq. 3) of the remaining sequence variants passing all filtering criteria. 293 sequences of the predicted binders have a higher overall developability improvement score than the maximum score identified from an experimental binder. **(i)** Filtering parameters and the number of sequences at the corresponding stage of filtering.